Aligos Therapeutics, Inc. last reported quarterly results on Nov 6, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $2.8 million (+281.9% year over year) and diluted EPS of -$2.09. It usually reports 37–64 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 4, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Mar 5, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–64 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 6, 2026
37 days after quarter end
From press release
|
Q3 FY2026
ended Sep 30, 2026
|
3
+281.9%
|
-22
+30.7%
|
-2.09
+31.3%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-100.0%
|
-2
+90.5%
|
-0.14
+90.8%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
3
+810.0%
|
-23
-153.5%
|
-2.21
-4.7%
|
|
Mar 5, 2026
64 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
-72.1%
|
-20
+75.8%
|
-1.91
+85.4%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
-40.7%
|
-32
-63.8%
|
-3.04
+1.0%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
-9.0%
|
-16
-413.4%
|
-1.53
-288.9%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
-55.2%
|
43
+223.6%
|
-2.11
+62.2%
|
|
Mar 10, 2025
69 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1
-9.8%
|
-82
-194.5%
|
-13.08
-136.0%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ALGS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1799448
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.